Epithalon vs MOTS-c
Epithalon and MOTS-c are both studied for longevity — but they target aging through entirely different mechanisms. Epithalon activates telomerase (hTERT) to elongate telomeres and modulates epigenetic methylation, addressing the replicative senescence axis of aging. MOTS-c activates AMPK to drive metabolic flexibility and mitochondrial biogenesis, addressing the metabolic axis. This guide breaks down the mechanisms, the evidence, and when to use each.
Telomere maintenance, replicative senescence, circadian rhythm regulation, retinal degeneration, or cancer prevention research.
Insulin resistance, metabolic syndrome, visceral fat, mitochondrial biogenesis, or broad metabolic longevity protocols.
Mechanism Deep Dive
Epithalon
Target: Telomerase (hTERT) — the enzyme that adds TTAGGG repeats to telomere ends, preventing replicative shortening and cellular senescence.
Mechanism: Epithalon reduces DNA methylation of the hTERT promoter, allowing telomerase expression in somatic cells that normally suppress it. It also modulates the pineal gland to normalize melatonin secretion — relevant for circadian rhythm, immune function, and antioxidant protection of telomeric DNA.
Net effect: Telomere elongation in aging cells, reduced replicative senescence, improved circadian rhythm, and potential cancer-preventive effects via genomic stability.
Unique advantage: The only peptide with a direct telomerase activation mechanism and Russian clinical longevity outcome data (reduced cancer incidence, extended lifespan).
MOTS-c
Origin: Encoded within the 12S rRNA gene of mitochondrial DNA — one of the first mitochondria-derived peptides (MDPs) discovered to have systemic hormonal effects.
Mechanism: MOTS-c translocates to the nucleus under metabolic stress and activates AMPK. AMPK activation drives: glucose uptake via GLUT4 translocation, fatty acid oxidation, mitochondrial biogenesis via PGC-1α, and inhibition of mTOR.
Net effect: Improved insulin sensitivity, reduced visceral fat, enhanced fatty acid oxidation, and increased mitochondrial number and efficiency.
Unique advantage: Systemic metabolic effects via AMPK — the same pathway activated by metformin and exercise. Acts as an endogenous "exercise mimetic" and longevity signal.
Hallmarks of Aging: Which Each Peptide Addresses
Research use only. Compound Review scores vendors on documentation — laboratory certificates, lot records, pricing and company identity. Nothing on this page is guidance on human or veterinary use, dosing or health outcomes.
Pathway Comparison Diagram
Epithalon activates TERT to elongate telomeres for cellular longevity; MOTS-c activates AMPK to drive mitochondrial biogenesis and metabolic regulation.
Head-to-Head Comparison
| Aspect | Epithalon | MOTS-c |
|---|---|---|
| Peptide class | Tetrapeptide (Ala-Glu-Asp-Gly) | Mitochondria-derived peptide (MDP), 16 residues |
| Origin | Synthetic analog of Epithalamin (pineal gland extract) | Encoded within 12S rRNA of mitochondrial DNA |
| Primary target | Telomerase (hTERT) activation; epigenetic regulation via DNA methylation | AMPK → PGC-1α → mitochondrial biogenesis and insulin sensitization |
| Mechanism of action | Activates telomerase to elongate telomeres; reduces DNA methylation of hTERT promoter; modulates melatonin secretion via pineal gland | Activates AMPK to improve insulin sensitivity, fatty acid oxidation, mitochondrial turnover, and glucose uptake |
| Primary longevity pathway | Telomere maintenance → reduced replicative senescence | Metabolic flexibility → reduced metabolic aging and mitochondrial dysfunction |
| Human clinical data | Russian clinical trials (1980s–2000s): reduced cancer incidence, extended lifespan in elderly cohorts; not peer-reviewed by Western standards | Phase 1 safety data only; no published human efficacy RCTs as of 2026 |
| Primary research use | Longevity, cancer prevention, circadian rhythm regulation, retinal degeneration | Insulin resistance, metabolic syndrome, obesity, exercise mimetic effects |
| Route of administration | Subcutaneous injection or intranasal (research) | Subcutaneous injection (research) |
| Half-life | ~1–2 hours (SC) | ~2–4 hours (SC) |
| Cycle length | 10–20 day cycles, 1–2x per year | 8–16 weeks with cycling |
| Synergy potential | Pairs with GHK-Cu, NAD+, Thymalin for comprehensive anti-aging | Pairs with SS-31, NAD+, GLP-1 for metabolic protocols |
| Regulatory status | Research chemical; no IND or approved indication in Western markets | Research chemical; no IND or approved indication |
| Evidence strength | Extensive Russian clinical data; limited Western peer-reviewed evidence | Preclinical + Phase 1 only; human efficacy unproven |
Evidence Summary
Epithalon Evidence
Russian Clinical TrialsRussian clinical trials (Khavinson et al., St. Petersburg Institute of Bioregulation and Gerontology): Epithalon reduced cancer incidence and extended lifespan in elderly cohorts over 12–15 year follow-up periods. These studies are not peer-reviewed by Western journal standards but represent the most extensive clinical longevity data for any peptide.
Preclinical studies confirm Epithalon activates hTERT and elongates telomeres in human fetal fibroblasts, somatic cells, and animal models. The mechanism (hTERT promoter demethylation) is mechanistically plausible and reproducible in vitro.
Russian clinical data for retinal pigment epithelium protection in age-related macular degeneration. Preclinical data in retinitis pigmentosa models.
MOTS-c Evidence
Phase 1 + PreclinicalLee et al. (Cell Metabolism, 2015) identified MOTS-c as a mitochondria-derived peptide that regulates insulin sensitivity via AMPK. Foundational paper establishing the MDP concept and the mitochondria-to-nucleus signaling pathway.
Reynolds et al. (Nature Communications, 2021): MOTS-c levels increase with exercise in humans; exogenous MOTS-c improved exercise capacity in aged mice. Suggests an endogenous exercise-longevity signaling role.
Phase 1 safety data available; well-tolerated at research doses. No published Phase 2 efficacy RCTs in humans as of 2026.
What the cited studies used
One row per compound: the amount and schedule administered in a specific indexed study, who received it, and the paper. These are reports of what was done in that study, not recommendations, and several are animal or single-dose studies. Where no indexed human regimen exists we say so rather than print a number. Community "stacks" and cycle schedules are not reproduced on this site.
Research use only. Compound Review scores vendors on documentation — laboratory certificates, lot records, pricing and company identity. Nothing on this page is guidance on human or veterinary use, dosing or health outcomes.
| Compound | Regimen in the study | Population | Source |
|---|---|---|---|
| Epithalon (epitalon) | 1.0 µg per mouse (≈30–40 µg/kg) subcutaneous, five consecutive days each month, from age 3 months for life The telomerase finding (Khavinson 2003, PMID 12937682) is in cultured human fibroblasts — no dose applies to a person. | Female SHR mice (life-span and tumour-incidence study) | PMID 14501183 Anisimov et al., Biogerontology 2003 |
| MOTS-c | Intraperitoneal injection in mice (the amount is in the paper's methods, not its abstract; we do not reproduce it) No human interventional trial. Reynolds 2021 (PMID 33473109) adds late-life mouse dosing and human plasma observations after exercise — not administration to people. | Mice — age-related and high-fat-diet insulin resistance models | PMID 25738459 Lee et al., Cell Metab 2015 |
| NAD+ (via nicotinamide riboside) | Nicotinamide riboside 1,000 mg/day oral (500 mg twice daily) for 6 weeks A 2 × 6-week crossover of an oral precursor (the abstract states the design; the 500 mg twice-daily amount is in the methods). We have no PubMed-indexed trial of intravenous NAD+ at the gram amounts sold by clinics. | Healthy middle-aged and older adults (n = 24), randomised crossover | PMID 29599478 Martens et al., Nat Commun 2018 |
Which Should You Research? — Decision Matrix
| Research Goal | Recommended | Rationale |
|---|---|---|
| Telomere maintenance / replicative senescence | Epithalon | Direct hTERT activation; the only peptide with a telomerase-specific mechanism; Russian clinical longevity data |
| Insulin resistance / metabolic syndrome | MOTS-c | AMPK activation improves insulin sensitivity and fatty acid oxidation; no Epithalon data for metabolic endpoints |
| Circadian rhythm / melatonin regulation | Epithalon | Pineal gland modulation; evidence for melatonin normalization in elderly; no MOTS-c circadian data |
| Mitochondrial biogenesis | MOTS-c | Direct PGC-1α activation via AMPK; Epithalon has no direct mitochondrial biogenesis mechanism |
| Cancer prevention / tumor suppression | Epithalon (slight edge) | Russian clinical data shows reduced cancer incidence; MOTS-c has limited oncology data. Neither has Western RCT data for this endpoint. |
| Retinal degeneration / eye health | Epithalon | Preclinical and Russian clinical data for retinal protection; no MOTS-c retinal data |
| Broad longevity / anti-aging | Stack both | Complementary mechanisms — Epithalon for telomere/epigenetic axis; MOTS-c for metabolic/mitochondrial axis. No head-to-head longevity data. |
| Budget-constrained single compound | MOTS-c | Lower cost per cycle; broader metabolic applicability; more consistent supply chain as research chemical |
Frequently Asked Questions
What is the difference between Epithalon and MOTS-c?
Epithalon is a synthetic tetrapeptide that activates telomerase (hTERT) to elongate telomeres and modulates epigenetic methylation patterns — targeting the replicative senescence axis of aging. MOTS-c is a naturally occurring mitochondria-derived peptide that activates AMPK to improve insulin sensitivity, fatty acid oxidation, and mitochondrial biogenesis — targeting the metabolic axis of aging. They address aging through entirely different mechanisms and are highly complementary.
Can Epithalon and MOTS-c be stacked together?
Yes — Epithalon and MOTS-c have non-overlapping mechanisms that make them a logical combination for comprehensive longevity protocols. Epithalon addresses telomere maintenance and epigenetic regulation; MOTS-c addresses metabolic flexibility and mitochondrial biogenesis. The combination covers two of the major hallmarks of aging (telomere attrition and mitochondrial dysfunction) simultaneously. No human stacking data exists, but the mechanistic rationale is well-supported by preclinical research.
What is Epithalon used for in research?
Epithalon is primarily researched for longevity, telomere maintenance, and cancer prevention. Its mechanism involves activating telomerase (hTERT) to elongate telomeres, which reduces replicative senescence in aging cells. It also modulates the pineal gland to normalize melatonin secretion, which is relevant for circadian rhythm regulation and immune function. Russian clinical trials (conducted by the St. Petersburg Institute of Bioregulation and Gerontology) reported reduced cancer incidence and extended lifespan in elderly cohorts, though these studies have not been replicated in Western peer-reviewed RCTs.
Does Epithalon actually lengthen telomeres?
Preclinical evidence supports Epithalon's ability to activate telomerase (hTERT) and elongate telomeres in cell culture and animal models. The mechanism involves reducing DNA methylation of the hTERT promoter, which allows telomerase expression in somatic cells that normally suppress it. Human data is limited to Russian clinical studies that measured indirect longevity endpoints (cancer incidence, mortality) rather than direct telomere length measurements. No Western peer-reviewed RCT has directly measured telomere elongation in humans after Epithalon administration.
What is MOTS-c's role in longevity research?
MOTS-c is studied as a mitochondria-derived longevity signal — one of the first peptides discovered to be encoded within mitochondrial DNA and to have systemic hormonal effects. Its primary longevity mechanism is AMPK activation, which drives mitochondrial biogenesis (via PGC-1α), improves insulin sensitivity, and inhibits mTOR — all pathways associated with extended lifespan in model organisms. Reynolds et al. (Nature Communications, 2021) found that MOTS-c levels increase with exercise in humans and that exogenous MOTS-c improved exercise capacity in aged mice, suggesting it may be an endogenous exercise-longevity signal.
How does Epithalon compare to other telomere-targeting compounds?
Epithalon is the most studied peptide telomerase activator. Other telomere-targeting approaches include TA-65 (a cycloastragenol-based small molecule telomerase activator derived from Astragalus), GHK-Cu (which has indirect epigenetic effects on telomere-associated genes), and NAD+ precursors (which support PARP-mediated DNA repair at telomeres). Epithalon is unique in its direct hTERT promoter demethylation mechanism and its pineal gland modulation. TA-65 has more Western peer-reviewed data; Epithalon has more clinical longevity outcome data (from Russian studies).
What are the side effects of Epithalon and MOTS-c?
Epithalon has a favorable safety profile in Russian clinical trials and research use. The most commonly reported effects are mild injection site reactions. Theoretical concerns include the possibility that telomerase activation could promote cancer cell proliferation, though Russian clinical data showed reduced (not increased) cancer incidence. MOTS-c has limited human safety data. Preclinical studies show a favorable profile; the most commonly reported effects in research use are mild injection site reactions and transient hypoglycemia at higher doses in insulin-sensitive individuals.